# An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Study · id `cardio:ct-nct07234032` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07234032](<https://clinicaltrials.gov/study/NCT07234032>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07234032

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 344 participants.

## Technical summary

Registry record NCT07234032. Allocation not applicable; no masking; primary purpose treatment. Start 2026-07-20 (actual); primary completion 2031-01-22 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 344 participants (planned count; ClinicalTrials.gov record NCT07234032, source copy `cardio:ctgov-nct07234032-2026-11-10`, retrieved 2026-11-18)
- Started: 2026-07-20 (actual) (ClinicalTrials.gov record NCT07234032, source copy `cardio:ctgov-nct07234032-2026-11-10`, retrieved 2026-11-18)
- Primary completion: 2031-01-22 (anticipated) (ClinicalTrials.gov record NCT07234032, source copy `cardio:ctgov-nct07234032-2026-11-10`, retrieved 2026-11-18)
- Completion: 2031-01-22 (anticipated) (ClinicalTrials.gov record NCT07234032, source copy `cardio:ctgov-nct07234032-2026-11-10`, retrieved 2026-11-18)
- Countries: United States; Czechia; France; Georgia; Germany; Japan; South Korea; Spain (ClinicalTrials.gov record NCT07234032, source copy `cardio:ctgov-nct07234032-2026-11-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07234032-2026-11-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Condition: Pulmonary Hypertension
- Condition: Interstitial Lung Disease
- Intervention (Drug): Treprostinil Palmitil Inhalation Powder
- Intervention (Drug): Placebo
- Lead sponsor: Insmed Incorporated
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Insmed Incorporated (`cardio:org-insmed-incorporated`)

## Provenance

Content hash: 589fba4f0cf6a75448f6249e95a2a0b124b545dcbab7b8dcb2c4725f2e4f3cd6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
